TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Abpro Holdings ( (ABP) ) just unveiled an update.
On November 3, 2025, Abpro Holdings, Inc. announced the effectiveness of a 1-for-30 reverse stock split that took place on October 31, 2025. This strategic move aims to maintain compliance with Nasdaq listing requirements and support the company’s growth phase. The reverse stock split reduces the number of outstanding shares from approximately 81.2 million to 2.7 million, with no fractional shares issued. Abpro has achieved a 60% reduction in operating costs and is leveraging its partnership with Celltrion to advance its lead antibody program, ABP-102, with a first-in-human trial expected in 2026. The company’s DiversImmune® and MultiMab™ platforms are also being evaluated to unlock further pipeline value.
The most recent analyst rating on (ABP) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Abpro Holdings stock, see the ABP Stock Forecast page.
More about Abpro Holdings
Abpro Holdings, Inc. is a biotechnology company focused on developing next-generation antibody therapies. The company is advancing a pipeline targeting HER2+ cancers, non-HER2+ gastric and liver cancer, and wet age-related macular degeneration and diabetic macular edema, utilizing its proprietary DiversImmune® platform. Abpro is located in Woburn, Massachusetts.
Average Trading Volume: 5,077,839
Technical Sentiment Signal: Sell
Current Market Cap: $14.79M
See more insights into ABP stock on TipRanks’ Stock Analysis page.